Ferring acquires global rights to Milprosa from Teva

29 September 2015

Privately-held Switzerland-based Ferring Pharmaceuticals has acquired the global rights to Milprosa (progesterone vaginal ring) from Teva Women’s Health, a US subsidiary of Israel’s Teva Pharmaceutical Industries (NYSE: TEVA).

Milprosa has the potential to be the first once-weekly progesterone treatment for luteal phase support in women undergoing assisted reproductive technology (ART) treatment if approved by regulatory authorities in the USA. Milprosa is a soft, flexible silicone-based vaginal ring designed to deliver a daily 11mg dose of progesterone over the course of one week.

“Ferring is a leader in infertility and Milprosa, if approved, would enhance our broad treatment portfolio in this area. Equally important to Ferring is that Milprosa would offer a weekly treatment regimen for patients and a new treatment option for doctors,” said Michel Pettigrew, president of the Ferring executive board and chief operating officer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK